An Exciting Month With a new trade marked name, more substantial news on testing (albeit a bit of a surprise) and nothing on the horizon that will fit the mass scale of testing required, Thrm still looks an exciting proposition.
Morningstar's Fair Value sp of $.53 is reachable in the near term and the 1-star valuation will continue to be extremely speculative until testing and the applications for approval are completed. Currently it sits at $2.82. Not unexpectedly Barchart has lowered their shorterm sentiment to a 56% Buy. The resistance levels are at $.45, $.555 and $.625. Getting back up between $.50 and $.60 would be a great level to move from on a solid NR.
Looking forward to seeing the launch of AcuVid.
GLTA!!,